Travel Vaccines Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 5 Billion |
| Market Size (2029) | USD 7.47 Billion |
| CAGR (2024 - 2029) | 8.33 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Travel Vaccines Market Analysis
The Travel Vaccines Market size is estimated at USD 5 billion in 2024, and is expected to reach USD 7.47 billion by 2029, growing at a CAGR of 8.33% during the forecast period (2024-2029).
Travel vaccination is the administration of agent-specific but safe antigenic components for the prevalent diseases at the traveler's destination. Vaccinated individuals can develop immunity against the corresponding infectious agent and thus remain protected.
Before departure, the World Health Organization (WHO) recommends that travelers have a medical consultation to learn about the disease risk in the destinations they plan to visit and the steps to avert illness. Such vaccinations are recommended to shield the traveler from the diseases prevalent in the country of origin or destination. They aim to protect travelers and avoid spreading disease within and between countries. Additionally, some countries need proof of vaccination for travelers wanting to enter or exit the country. Proof of vaccination for traveling is defined as a vaccination requirement in accordance with the International Health Regulations (IHR) of the WHO. Such guidelines and policies have raised awareness among travelers, prompting the growth of the travel vaccines market.
Furthermore, after the COVID-19 pandemic, inbound tourism witnessed a significant uptick from most revered travel destinations. For instance, as per data from the United Nations World Tourism Organization (UNWTO), Italy witnessed 74.32 million tourist arrivals in 2022, compared to 40.19 million in 2021 and 38.42 million in 2020. Similarly, Türkiye recorded 51.39 million tourist arrivals in 2022, compared to 15.97 million in 2020. Hence, such a rise in outbound tourism positively impacts demand for travel vaccines and is projected to drive market growth over the next few years.
In addition, meetings, incentives, conferences, and exhibitions (MICE) tourism is witnessing strong growth across different nations. For instance, in October 2023, the Thailand Convention and Exhibition Bureau (TCEB) unveiled its strategic direction for 2024 to transform the country’s MICE industry. Similarly, the Indian Ministry of Tourism unveiled the National Strategy and Roadmap for the MICE industry in June 2021 to promote MICE tourism in India. According to the Confederation of Indian Industry (CII), the exhibition industry in the country is rapidly growing at a rate of more than 8% and is outpacing the GDP growth rate of the country. Such initiatives are expected to increase MICE-related travel to these destinations from various countries, prompting the requirement for travel vaccines. Such factors are expected to boost the growth of the travel vaccines market.
However, most travelers from developing nations have limited awareness about travel vaccines despite constituting a large share of global outbound tourism. Such factors may restrain market growth.
Travel Vaccines Market Trends
The Hepatitis A Segment is Expected to Witness Significant Growth During the Forecast Period
According to the WHO, the hepatitis A virus has a global distribution trend and triggers ~1.5 million cases of clinical hepatitis each year. It estimates that most adults from developing nations have serological evidence of infection with the hepatitis A virus. The transmission occurs predominantly through the fecal-oral route and is directly associated with poor sanitary conditions. Bloodborne transmission of hepatitis A virus is relatively uncommon, though cases have been noted in the past.
Hepatitis A is an utterly common vaccine-preventable infection, often acquired during travel. Cases of travel-related hepatitis A generally occur in travelers who backpack to developed and developing countries and who have standard tourist accommodations, eating behaviors, and itineraries. Risk is paramount for those traveling to rural areas, frequently eating or drinking in settings with poor sanitation, or trekking in backcountry areas.
The CDC recommends vaccination as the best method to remain protected against hepatitis A. It recommends the vaccine for international travelers, six months of age or older, traveling to countries where the disease is common. The CDC also advises additional protection against hepatitis B by taking a combination vaccine, which is usually given in three doses.
Given the wide prevalence of the disease, coupled with the rising awareness of the benefits of the hepatitis A vaccine, there is an increasing demand for the same among international travelers to developing nations. Such factors are projected to drive segmental growth over the forecast period.
North America is Expected to Dominate the Travel Vaccines Market
North America is expected to dominate the travel vaccines market owing to factors such as the broad awareness of the benefits of travel vaccines, developed healthcare infrastructure, strong regulations from different government authorities, and the presence of established players in the region. The residents of the United States are known for traveling to various countries of the world. The US Travel Association estimates that 2.51 billion trips will be made by US residents in 2024, and the number will increase to 2.61 billion by 2026. Of these, 75.4 million are expected to be international trips in 2024 and will increase to 89.3 million in 2026.
According to the Japan National Tourism Organization (JNTO), 2.05 million US residents traveled to Japan in 2023, compared to 0.32 million in 2022 and 1.72 million in 2019. Such travel to tropical nations is anticipated to boost the adoption of travel vaccines, thus influencing market growth in the region.
Furthermore, several prominent players in the market are focused on expanding their geographical presence, which, in turn, is projected to create numerous growth opportunities for the market, thereby influencing market growth in the region. For instance, in September 2023, ByoRNA SAS, a French biotechnology company developing scalable mRNA bioproduction platforms, partnered with Florida-based Dyadic International Inc. to explore advanced bioproduction technologies to utilize the potential of messenger RNA (mRNA). Such strategic initiatives by critical players may further contribute to market growth.
Travel Vaccines Industry Overview
The travel vaccines market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold significant market share and are well known, including Abbott Laboratories, AstraZeneca plc, CSL Ltd, F. Hoffmann-La Roche AG, GSK PLC, Janssen Pharmaceuticals, Pfizer Inc, Qiagen NV, Sanofi SA, and Valneva SE.
Travel Vaccines Market Leaders
-
Abbott Laboratories
-
AstraZeneca plc
-
GSK plc
-
Pfizer Inc
-
Valneva SE
*Disclaimer: Major Players sorted in no particular order
Travel Vaccines Market News
- March 2024: The UAE Ministry of Health and Prevention (MoHAP) mandated influenza vaccination for pilgrims traveling to Saudi Arabia. It was a preventive measure to protect the Hajj performers, their families, and all segments of society from infectious diseases.
- February 2024: The University of Kentucky’s UK Retail Pharmacies started offering travelers all the required and recommended vaccines based on their destination, including yellow fever, typhoid, and cholera.
- May 2023: Bavarian Nordic acquired Emergent BioSolutions’ travel vaccine portfolio for USD 274 million. The deal encompassed the acquisition of vaccines Vivotif and Vaxchora, marketed for the prevention of typhoid and cholera, respectively, and a phase III vaccine candidate for the prevention of the chikungunya virus.
Travel Vaccines Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Significant Rise in Outbound Tourism
- 4.2.2 Prevalence of Hepatitis A Across Most Travelled Destinations
- 4.2.3 Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations
-
4.3 Market Restraints
- 4.3.1 Lack of Knowledge Among Travellers from Developing Nations
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Type
- 5.1.1 Cholera
- 5.1.2 Diptheria Pertussis Tetanus (DPT)
- 5.1.3 Encephalitis
- 5.1.4 Hepatitis A
- 5.1.5 Meningococcal
- 5.1.6 Rabies
- 5.1.7 Typhoid
- 5.1.8 Yellow Fever
- 5.1.9 Other Types
-
5.2 By Travel Type
- 5.2.1 Domestic
- 5.2.2 Outbound
-
5.3 By Vaccination Center
- 5.3.1 Hospitals
- 5.3.2 Travel Clinics
- 5.3.3 Other Vaccination Centers
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 AstraZeneca PLC
- 6.1.3 CSL Ltd
- 6.1.4 F. Hoffmann-La Roche AG
- 6.1.5 GSK PLC
- 6.1.6 Janssen Pharmaceuticals
- 6.1.7 Pfizer Inc.
- 6.1.8 Qiagen NV
- 6.1.9 Sanofi SA
- 6.1.10 Valneva SE
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityTravel Vaccines Industry Segmentation
Vaccinations are a critical component in the travel medicine industry. Beyond the protection of travelers, vaccines are administered to stop the introduction of vaccine-preventable diseases at home and their destination. The WHO endorses internationally recognized certificates with proof of poliomyelitis vaccination in certain circumstances, proof of yellow fever vaccination for entry into certain countries, and proof of meningococcal vaccination for Hajj pilgrims.
The travel vaccines market is segmented by type, travel type, vaccination center, and geography. By type, the market is segmented into cholera, diphtheria pertussis tetanus (DPT), encephalitis, hepatitis A, meningococcal, rabies, typhoid, yellow fever, and other types. Based on travel type, the market is bifurcated into domestic and outbound. The travel vaccines market is segmented by vaccination centers into hospitals, travel clinics, and other vaccination centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. For each segment, the market size and forecast are provided in terms of value (USD).
| By Type | Cholera | |
| Diptheria Pertussis Tetanus (DPT) | ||
| Encephalitis | ||
| Hepatitis A | ||
| Meningococcal | ||
| Rabies | ||
| Typhoid | ||
| Yellow Fever | ||
| Other Types | ||
| By Travel Type | Domestic | |
| Outbound | ||
| By Vaccination Center | Hospitals | |
| Travel Clinics | ||
| Other Vaccination Centers | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Travel Vaccines Market Research FAQs
How big is the Travel Vaccines Market?
The Travel Vaccines Market size is expected to reach USD 5 billion in 2024 and grow at a CAGR of 8.33% to reach USD 7.47 billion by 2029.
What is the current Travel Vaccines Market size?
In 2024, the Travel Vaccines Market size is expected to reach USD 5 billion.
Who are the key players in Travel Vaccines Market?
Abbott Laboratories, AstraZeneca plc, GSK plc, Pfizer Inc and Valneva SE are the major companies operating in the Travel Vaccines Market.
Which is the fastest growing region in Travel Vaccines Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Travel Vaccines Market?
In 2024, the North America accounts for the largest market share in Travel Vaccines Market.
What years does this Travel Vaccines Market cover, and what was the market size in 2023?
In 2023, the Travel Vaccines Market size was estimated at USD 4.58 billion. The report covers the Travel Vaccines Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Travel Vaccines Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Travel Vaccines Industry Report
Statistics for the 2024 Travel Vaccines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Travel Vaccines analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
